{"prompt": "['i. sedative hypnotics (with the exception of zolpidem as needed, no', 'more than 3 times per week, allowed during the screening period', 'and the first 2 weeks of the treatment period); Note: If zolpidem is', 'not available in specific regions, another sedative hypnotic may be', 'approved by the Medical Monitor.', 'ii. central opioid agonists/antagonists including tramadol;', 'iii. anticonvulsants;', 'iv. mood stabilizers, antipsychotics, antidepressants;', 'V. methotrexate;', 'vi. any known 5-HT2A receptor antagonist or inverse agonist including', 'but not limited to mianserin, mirtazapine, nefazodone,', 'cyproheptadine, pimavanserin, or fluvoxamine;', 'vii. immunosuppressants;', 'viii. dietary supplements, medical foods, or pharmaceuticals containing', \"Omega-3 fatty acids, melatonin, St. John's Wort, kava kava,\", 'Vitamin B12, folate (no L-methylfolate in current episode), or', 'valerian root. Daily multivitamin use is not excluded.', '14. The patient has abnormal laboratory values or clinical findings at screening that', 'are judged clinically significant and confirmed upon re-test (1 re-test prior to', 'baseline visit is allowed and results must be available prior to the baseline visit', 'and must have returned to within normal range), including, but not limited to:', 'a. Aspartate aminotransferase (AST) >2.0 x the upper limit of normal (ULN)', 'b. Alanine aminotransferase (ALT) >2.0 x the ULN', 'C. Alkaline phosphatase >2.0 x the ULN', 'd. Gamma-glutamyl transpeptidase >2.0 x the ULN', 'e. Total bilirubin >1.5 x the ULN', 'f.', 'Serum creatinine >1.5 x the ULN', 'g. Blood urea nitrogen >1.5 x the ULN', 'h. Thyroid-stimulating hormone outside of the normal limits and clinically', 'significant, as determined by the investigator. Free thyroxine levels may', 'be measured if thyroid-stimulating hormone level is high. The patient will', 'be excluded if the free thyroxine level is clinically significant.', 'Intra-Cellular Therapies, Inc. Confidential', '16 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['i.', '12-lead ECG (in a supine position after a rest of approximately 10 minutes', 'at the screening visit) mean of triplicate corrected QT interval using the', 'Fridericia formula (QTcF) >450 ms for males or females, corrected QT', 'interval using the Bazett formula (QTcB) >450 ms for males or >470 ms for', 'females, and/or heart rate <50 beats per minute, or evidence of clinically', 'significant bundle-branch blocks.', 'j.', 'Any other clinically significant abnormal laboratory result at the time of the', 'screening examination. Note: medical conditions that are stable with', 'medication (e.g., hypertension, high cholesterol, and hyperthyroidism) are', 'allowed as long as the condition has been stable for at least 3 months', 'prior to screening, the medications are documented and kept stable during', 'the study, and the condition is not thought to affect safe participation in the', 'study in the opinion of the investigator and confirmed by the Medical', 'Monitor as part of the screening adjudication process.', '15. The patient has clinically significant cardiovascular (including but not limited to', 'uncontrolled angina, or history of a myocardial infarction within 3 months prior to', 'screening, or history of a clinically significant cardiac arrhythmia including', 'antipsychotic drug-induced corrected QT interval prolongation), endocrine', '(including poorly controlled diabetes defined as glycated hemoglobin A1c', '[HbA1c] >53 mmol/mol [7.0%] at screening with no re-test allowed for HbA1c),', 'hepatic, renal, pulmonary, gastrointestinal, neurological, malignancy (including', 'any malignancy and/or chemotherapy within the 2 years prior to screening;', 'malignancy more than 2 years prior to screening must have been local and', 'without metastasis and/or recurrence, and if treated with chemotherapy, without', 'nervous system complications; some malignancies, such as basal cell carcinoma,', 'may not preclude participation and will be individually reviewed),', 'pheochromocytoma metabolic, psychiatric or other condition that might be', 'detrimental to the patient if he or she participates in the study (in the opinion of', 'the investigator).', '16. The patient has a history of human immunodeficiency virus (HIV) infection or has', 'HIV antibodies in blood at screening.', '17. The patient has a history of hepatitis B or hepatitis C infection or shows evidence', 'of active hepatitis B or hepatitis C infection at screening.', '18. The patient is unable to be safely discontinued from current antidepressant', 'medication, mood stabilizers, anticholinergics, or other psychotropic medications', '(in the opinion of the investigator).', '19. The patient is judged by the investigator to be inappropriate for the study.', 'Intra-Cellular Therapies, Inc. Confidential', '17 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}